1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Alloxan Diabetes in 39 studies
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Further, perivascular and myocardial fibrosis, arterial intimal thickening were assessed by histology, and capillary density, nitrotyrosine and ROCK1/2 expressions were evaluated by immunohistochemical staining." | 3.79 | Acute Rho-kinase inhibition improves coronary dysfunction in vivo, in the early diabetic microcirculation. ( Edgley, AJ; Fujii, Y; Jenkins, MJ; Joshi, M; Kelly, DJ; Pearson, JT; Schwenke, DO; Shirai, M; Sonobe, T; Tsuchimochi, H; Umetani, K; Waddingham, MT; Yoshimoto, M, 2013) |
| "Fasudil co-treatment normalized the high-glucose-induced upregulation of these mediators." | 1.48 | Rho-Associated Protein Kinase-1 Mediates the Regulation of Inflammatory Markers in Diabetic Retina and in Retinal Müller Cells. ( Abu El-Asrar, AM; Ahmad, A; Alam, K; AlSharif, HM; Mohammad, G; Siddiquei, MM, 2018) |
| "Treatment with fasudil or captopril suppressed not only the inflammation reaction but also the accumulation of the extracellular matrix due to the downregulation of TGF-β1 and MMP-9/TIMP-1, which induces the amelioration of the liver fibrosis with diabetes." | 1.48 | Fasudil alleviates hepatic fibrosis in type 1 diabetic rats: involvement of the inflammation and RhoA/ROCK pathway. ( Chu, L; Huo, M; Ma, ZH; Song, T; Wang, N; Xie, Y; Zhang, JP; Zhang, Y; Zhang, YY, 2018) |
| "In fasudil-treated rats, the internal carotid artery narrowing was ameliorated and L-NAME-induced regional constriction was abolished." | 1.43 | Vessel Dilation Attenuates Endothelial Dysfunction Following Middle Cerebral Artery Occlusion in Hyperglycemic Rats. ( Jiang, Z; Lin, XJ; Mu, ZH; Wang, LP; Wang, YT; Xi, Y; Yang, GY; Zhang, ZJ, 2016) |
| "Hyperglycemia and hyperlipidemia directly affected the contractile function of VSMCs." | 1.42 | Diabetes and hyperlipidemia induce dysfunction of VSMCs: contribution of the metabolic inflammation/miRNA pathway. ( Chen, XY; Lan, D; Li, T; Liu, LM; Tian, KL; Wu, Y; Yang, GM; Zhu, Y, 2015) |
| "Treatment with fasudil normalized these molecular and histologic alterations, and restored erectile function." | 1.37 | Chronic treatment with an oral rho-kinase inhibitor restores erectile function by suppressing corporal apoptosis in diabetic rats. ( Kim, SW; Li, WJ; Paick, JS; Park, K, 2011) |
| "Fasudil treatment notably attenuates renal interstitial fibrosis in diabetic rats." | 1.36 | The influence of fasudil on the epithelial-mesenchymal transdifferentiation of renal tubular epithelial cells from diabetic rats. ( Jia, R; Tu, Y; Wu, G, 2010) |
| "Atorvastatin has been employed in the present study as standard agent to improve vascular endothelial dysfunction." | 1.33 | Involvement of Rho-kinase in experimental vascular endothelial dysfunction. ( Shah, DI; Singh, M, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (15.38) | 18.2507 |
| 2000's | 7 (17.95) | 29.6817 |
| 2010's | 25 (64.10) | 24.3611 |
| 2020's | 1 (2.56) | 2.80 |
| Authors | Studies |
|---|---|
| Xie, F | 1 |
| Lei, J | 1 |
| Ran, M | 1 |
| Li, Y | 2 |
| Deng, L | 1 |
| Feng, J | 1 |
| Zhong, Y | 1 |
| Li, J | 1 |
| Hofni, A | 1 |
| Shehata Messiha, BA | 1 |
| Mangoura, SA | 1 |
| Rothschild, PR | 1 |
| Salah, S | 1 |
| Berdugo, M | 1 |
| Gélizé, E | 1 |
| Delaunay, K | 1 |
| Naud, MC | 1 |
| Klein, C | 1 |
| Moulin, A | 1 |
| Savoldelli, M | 1 |
| Bergin, C | 1 |
| Jeanny, JC | 1 |
| Jonet, L | 1 |
| Arsenijevic, Y | 1 |
| Behar-Cohen, F | 1 |
| Crisanti, P | 1 |
| Mohammad, G | 1 |
| AlSharif, HM | 1 |
| Siddiquei, MM | 1 |
| Ahmad, A | 1 |
| Alam, K | 1 |
| Abu El-Asrar, AM | 1 |
| Xie, Y | 1 |
| Song, T | 1 |
| Huo, M | 1 |
| Zhang, Y | 1 |
| Zhang, YY | 1 |
| Ma, ZH | 2 |
| Wang, N | 1 |
| Zhang, JP | 2 |
| Chu, L | 2 |
| Mishra, RK | 1 |
| Alokam, R | 1 |
| Sriram, D | 1 |
| Yogeeswari, P | 1 |
| Guo, R | 1 |
| Liu, B | 1 |
| Zhou, S | 1 |
| Zhang, B | 1 |
| Xu, Y | 1 |
| Pearson, JT | 2 |
| Jenkins, MJ | 1 |
| Edgley, AJ | 2 |
| Sonobe, T | 1 |
| Joshi, M | 1 |
| Waddingham, MT | 2 |
| Fujii, Y | 2 |
| Schwenke, DO | 1 |
| Tsuchimochi, H | 2 |
| Yoshimoto, M | 1 |
| Umetani, K | 1 |
| Kelly, DJ | 2 |
| Shirai, M | 2 |
| Sezen, SF | 1 |
| Lagoda, G | 1 |
| Musicki, B | 1 |
| Burnett, AL | 1 |
| Kiss, A | 2 |
| Tratsiakovich, Y | 2 |
| Gonon, AT | 2 |
| Fedotovskaya, O | 1 |
| Lanner, JT | 1 |
| Andersson, DC | 1 |
| Yang, J | 2 |
| Pernow, J | 2 |
| Li, T | 1 |
| Yang, GM | 1 |
| Zhu, Y | 1 |
| Wu, Y | 1 |
| Chen, XY | 1 |
| Lan, D | 1 |
| Tian, KL | 1 |
| Liu, LM | 1 |
| Jin, J | 1 |
| Peng, C | 1 |
| Wu, SZ | 1 |
| Chen, HM | 1 |
| Zhang, BF | 1 |
| Astolfo, A | 1 |
| Inagaki, T | 1 |
| Du, CK | 1 |
| Zhan, DY | 1 |
| Yagi, N | 1 |
| Wang, J | 1 |
| Wen, CY | 1 |
| Cui, CC | 1 |
| Xing, Y | 1 |
| Mu, ZH | 1 |
| Jiang, Z | 1 |
| Lin, XJ | 1 |
| Wang, LP | 1 |
| Xi, Y | 1 |
| Zhang, ZJ | 1 |
| Wang, YT | 1 |
| Yang, GY | 1 |
| Peng, H | 1 |
| Wang, C | 1 |
| Zhang, J | 1 |
| Chen, Y | 1 |
| Chen, W | 1 |
| Cao, J | 1 |
| Wang, Y | 1 |
| Hu, Z | 1 |
| Lou, T | 1 |
| Vasam, G | 1 |
| Joshi, S | 1 |
| Thatcher, SE | 1 |
| Bartelmez, SH | 1 |
| Cassis, LA | 1 |
| Jarajapu, YP | 1 |
| Sjöquist, PO | 1 |
| Arita, R | 1 |
| Hata, Y | 1 |
| Nakao, S | 1 |
| Kita, T | 1 |
| Miura, M | 1 |
| Kawahara, S | 1 |
| Zandi, S | 1 |
| Almulki, L | 1 |
| Tayyari, F | 1 |
| Shimokawa, H | 1 |
| Hafezi-Moghadam, A | 1 |
| Ishibashi, T | 1 |
| Failli, P | 1 |
| Alfarano, C | 1 |
| Franchi-Micheli, S | 1 |
| Mannucci, E | 1 |
| Cerbai, E | 1 |
| Mugelli, A | 1 |
| Raimondi, L | 1 |
| Wu, G | 1 |
| Tu, Y | 1 |
| Jia, R | 1 |
| Kizub, IV | 1 |
| Pavlova, OO | 1 |
| Johnson, CD | 1 |
| Soloviev, AI | 1 |
| Zholos, AV | 1 |
| Li, WJ | 1 |
| Park, K | 1 |
| Paick, JS | 1 |
| Kim, SW | 1 |
| Nuno, DW | 1 |
| Lamping, KG | 1 |
| Komers, R | 1 |
| Oyama, TT | 1 |
| Beard, DR | 1 |
| Tikellis, C | 1 |
| Xu, B | 1 |
| Lotspeich, DF | 1 |
| Anderson, S | 1 |
| Hou, Y | 1 |
| Zhou, L | 1 |
| Yang, QD | 1 |
| Du, XP | 1 |
| Li, M | 1 |
| Yuan, M | 1 |
| Zhou, ZW | 1 |
| Guan, SJ | 1 |
| Wu, YL | 1 |
| Liang, F | 1 |
| Weiss, JW | 1 |
| Guo, QY | 1 |
| Wang, JY | 1 |
| Ji, ES | 1 |
| Kanazawa, Y | 2 |
| Takahashi-Fujigasaki, J | 1 |
| Ishizawa, S | 2 |
| Takabayashi, N | 1 |
| Ishibashi, K | 1 |
| Matoba, K | 1 |
| Kawanami, D | 1 |
| Yokota, T | 2 |
| Tajima, N | 2 |
| Utsunomiya, K | 2 |
| Büyükafşar, K | 1 |
| Un, I | 1 |
| Xie, Z | 1 |
| Su, W | 1 |
| Guo, Z | 1 |
| Pang, H | 1 |
| Post, SR | 1 |
| Gong, MC | 1 |
| Shah, DI | 1 |
| Singh, M | 1 |
| Lin, G | 1 |
| Craig, GP | 1 |
| Zhang, L | 1 |
| Yuen, VG | 1 |
| Allard, M | 1 |
| McNeill, JH | 1 |
| MacLeod, KM | 1 |
| Gojo, A | 1 |
| Taniguchi, K | 1 |
| Kurata, H | 1 |
| Craven, PA | 1 |
| Studer, RK | 1 |
| DeRubertis, FR | 1 |
| Sakai, Y | 1 |
| Inazu, M | 1 |
| Shamoto, A | 1 |
| Zhu, B | 1 |
| Homma, I | 1 |
| Hermenegildo, C | 2 |
| Felipo, V | 2 |
| Miñana, MD | 2 |
| Romero, FJ | 1 |
| Grisolía, S | 2 |
| Awazu, M | 1 |
| Parker, RE | 1 |
| Harvie, BR | 1 |
| Ichikawa, I | 1 |
| Kon, V | 1 |
| Gabbay, RA | 1 |
| Siconolfi-Baez, L | 1 |
| Lebovitz, HE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Influence of Treatment With the HMG-CoA-Reductase Inhibitor Fluvastatin on Erectile Function in Patients With Cardiovascular Risk-Factors and Erectile Dysfunction[NCT00382161] | Phase 3 | 20 participants (Anticipated) | Interventional | 2006-10-31 | Withdrawn (stopped due to not enough patients meeting inclusion criteria) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Alloxan Diabetes
| Article | Year |
|---|---|
Potential role of Rho kinase inhibitors in combating diabetes-related complications including diabetic neuropathy--a review.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Cardiomyopathies; Diabetes Complicat | 2013 |
38 other studies available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Alloxan Diabetes
| Article | Year |
|---|---|
Attenuation of Diabetic Nephropathy in Diabetic Mice by Fasudil through Regulation of Macrophage Polarization.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Glucose; Cell Polarity; Diabetes Melli | 2020 |
Fasudil ameliorates endothelial dysfunction in streptozotocin-induced diabetic rats: a possible role of Rho kinase.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Aorta, Thoracic; Diabetes Mellitus, Experime | 2017 |
ROCK-1 mediates diabetes-induced retinal pigment epithelial and endothelial cell blebbing: Contribution to diabetic retinopathy.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Animals; Biomarkers; Case-Control Studies; Cyto | 2017 |
Rho-Associated Protein Kinase-1 Mediates the Regulation of Inflammatory Markers in Diabetic Retina and in Retinal Müller Cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cells, Cultured; Chemokine CCL2; Cytokines; | 2018 |
Fasudil alleviates hepatic fibrosis in type 1 diabetic rats: involvement of the inflammation and RhoA/ROCK pathway.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Diabetes Mellitus, Experimental; Diabetes Me | 2018 |
The protective effect of fasudil on the structure and function of cardiac mitochondria from rats with type 2 diabetes induced by streptozotocin with a high-fat diet is mediated by the attenuation of oxidative stress.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Biomarkers; Cardiotonic Agents; Diabetes Mel | 2013 |
Acute Rho-kinase inhibition improves coronary dysfunction in vivo, in the early diabetic microcirculation.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Coronary Angiography; Coronary Circulation; | 2013 |
Hydroxyl fasudil, an inhibitor of Rho signaling, improves erectile function in diabetic rats: a role for neuronal ROCK.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blotting, Western; Diabetes Mellitus, Experi | 2014 |
The role of arginase and rho kinase in cardioprotection from remote ischemic perconditioning in non-diabetic and diabetic rat in vivo.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Arginase; Diabetes Mellitus, Experimental; E | 2014 |
Diabetes and hyperlipidemia induce dysfunction of VSMCs: contribution of the metabolic inflammation/miRNA pathway.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cells, Cultured; Connexins; Diabetes Mellitu | 2015 |
Blocking VEGF/Caveolin-1 signaling contributes to renal protection of fasudil in streptozotocin-induced diabetic rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Caveolin 1; Diabetes Mellitus, Experimental; | 2015 |
Chronic Rho-kinase inhibition improves left ventricular contractile dysfunction in early type-1 diabetes by increasing myosin cross-bridge extension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Animals; Diabetes Mellitus, Experimental; Dia | 2015 |
Effect of activation of the Ca(2+)-permeable acid-sensing ion channel 1a on focal cerebral ischemia in diabetic rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acid Sensing Ion Channels; Animals; Brain; Brain Isch | 2015 |
Vessel Dilation Attenuates Endothelial Dysfunction Following Middle Cerebral Artery Occlusion in Hyperglycemic Rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain; Cerebral Angiography; Cerebral Arteri | 2016 |
ROCK1 Induces Endothelial-to-Mesenchymal Transition in Glomeruli to Aggravate Albuminuria in Diabetic Nephropathy.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Albuminuria; Animals; Antigens, CD; Cadherins | 2016 |
Reversal of Bone Marrow Mobilopathy and Enhanced Vascular Repair by Angiotensin-(1-7) in Diabetes.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin I; Animals; Blood Vessels; Bone Marrow; B | 2017 |
Inhibition of Rho kinase protects from ischaemia-reperfusion injury via regulation of arginase activity and nitric oxide synthase in type 1 diabetes.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Arginase; Arginine; Cytoprotection; Diabetes | 2017 |
Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Apoptosis; Cell Adhesion; Diabetes Mellitus, | 2009 |
Losartan counteracts the hyper-reactivity to angiotensin II and ROCK1 over-activation in aortas isolated from streptozotocin-injected diabetic rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin II; Animals; Aorta, Thoracic; Biphenyl Co | 2009 |
The influence of fasudil on the epithelial-mesenchymal transdifferentiation of renal tubular epithelial cells from diabetic rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acetylglucosamine; Actins; Animals; beta Catenin; Blo | 2010 |
Rho kinase and protein kinase C involvement in vascular smooth muscle myofilament calcium sensitization in arteries from diabetic rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Arteries; Benzophenanthridines; Calcium; Dia | 2010 |
Chronic treatment with an oral rho-kinase inhibitor restores erectile function by suppressing corporal apoptosis in diabetic rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Oral; Animals; Apoptosis; Blotting, W | 2011 |
The role of rho kinase in sex-dependent vascular dysfunction in type 1 diabetes.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Diabetes Mellitus, Experimental; Diabetes Me | 2010 |
Rho kinase inhibition protects kidneys from diabetic nephropathy without reducing blood pressure.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin II Type 1 Receptor Blockers; Animals; Blo | 2011 |
Changes in hippocampal synapses and learning-memory abilities in a streptozotocin-treated rat model and intervention by using fasudil hydrochloride.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Diabetes Mellitus, Experimental; Disease Mod | 2012 |
Long-term administration of fasudil improves cardiomyopathy in streptozotocin-induced diabetic rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin-Converting Enzyme Inhibitors; Animals; An | 2012 |
The Rho-kinase inhibitor fasudil restores normal motor nerve conduction velocity in diabetic rats by assuring the proper localization of adhesion-related molecules in myelinating Schwann cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; beta Catenin; Body Weight; Cadherins; Cateni | 2013 |
Effects of the Rho-kinase inhibitors, Y-27632 and fasudil, on the corpus cavernosum from diabetic mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Diabetes Mellitus, Experimental; Dos | 2003 |
Up-regulation of CPI-17 phosphorylation in diabetic vasculature and high glucose cultured vascular smooth muscle cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Aorta; Cells, Cultured; Diabetes Mel | 2006 |
Involvement of Rho-kinase in experimental vascular endothelial dysfunction.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acetylcholine; Animals; Antibiotics, Antineoplastic; | 2006 |
Acute inhibition of Rho-kinase improves cardiac contractile function in streptozotocin-diabetic rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Amides; Animals; Blotting, Western; Cell Surv | 2007 |
The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 8-Hydroxy-2'-Deoxyguanosine; Albuminuria; Animals; Bl | 2007 |
Impaired nitric oxide-dependent cyclic guanosine monophosphate generation in glomeruli from diabetic rats. Evidence for protein kinase C-mediated suppression of the cholinergic response.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 1-Methyl-3-isobutylxanthine; 15-Hydroxy-11 alpha,9 al | 1994 |
Contractile hyperreactivity and alteration of PKC activity in gastric fundus smooth muscle of diabetic rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5 | 1994 |
Sustained recovery of Na(+)-K(+)-ATPase activity in sciatic nerve of diabetic mice by administration of H7 or calphostin C, inhibitors of PKC.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Diabetes Mellitus, Experimental; Dose-Respon | 1993 |
Inhibition of protein kinase C restores Na+,K(+)-ATPase activity in sciatic nerve of diabetic mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Diabetes Mellitus, Experimental; Dose-Respon | 1992 |
Down-regulation of endothelin-1 receptors by protein kinase C in streptozotocin diabetic rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin II; Animals; Blood Glucose; Diabetes Mell | 1991 |
Calcium-dependent protein kinase activity is decreased in diabetic rat sciatic nerve.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Calcium; Chromatography, Gel; Diabetes Melli | 1990 |